Full Press Release Details
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today that, on October 20, 2026, the Company will implement a 1-for-7 reverse split of its common stock. The reverse stock split will be effective as of the morning of October 20, 2026, and the Company’s common stock will trade on a post-split basis at the beginning of trading